Colinz Laboratories Limited share price
BSE: COLINZ
Key numbers
- Market cap
- ₹ 19.2 Cr
- Current price
- ₹ 76.20
- 52-week high / low
- ₹ 88 / 36
- Stock P/E
- 6.9
- Book value
- ₹ 39.9
- Dividend yield
- 0.00%
- ROCE
- 7.2%
- ROE
- 5.2%
- Debt to equity
- 0.04
- Sales growth (3 yrs)
- -4.9%
- Profit growth (3 yrs)
- 4.3%
- 1-year return
- 87.3%
About Colinz Laboratories Limited
Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2 | 1 | 1 | 2 | 1 |
| Operating profit | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 2 |
| EPS (₹) | 0.47 | 0.56 | 0.33 | - | 9.53 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.